Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Mihnea-Alexandru Gaman
 + 1905 word(s) 1905 2022-02-08 05:15:44 |
2 The format is correct
Lindsay Dong
 Meta information modification 1905 2022-02-10 04:12:02 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Gaman, M.; Gaman, A.M. The Involvement of Oxidative Stress in Psoriasis. Encyclopedia. Available online: https://encyclopedia.pub/entry/19264 (accessed on 27 September 2024).
Gaman M, Gaman AM. The Involvement of Oxidative Stress in Psoriasis. Encyclopedia. Available at: https://encyclopedia.pub/entry/19264. Accessed September 27, 2024.
Gaman, Mihnea-Alexandru, Amelia Maria Gaman. "The Involvement of Oxidative Stress in Psoriasis" Encyclopedia, https://encyclopedia.pub/entry/19264 (accessed September 27, 2024).
Gaman, M., & Gaman, A.M. (2022, February 09). The Involvement of Oxidative Stress in Psoriasis. In Encyclopedia. https://encyclopedia.pub/entry/19264
Gaman, Mihnea-Alexandru and Amelia Maria Gaman. "The Involvement of Oxidative Stress in Psoriasis." Encyclopedia. Web. 09 February, 2022.
The Involvement of Oxidative Stress in Psoriasis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/antiox11020282

Psoriasis is a chronic, immune-mediated inflammatory dermatosis characterized by the appearance of erythematous plaques, covered by white scales, occasionally pruritogenic, and distributed mainly on the extensor areas. Oxidative stress is defined as an imbalance or a transient or chronic increase in the levels of free oxygen/nitrogen radicals, either as a result of the exaggerated elevation in their production or the decrease in their ability to be eliminated by antioxidant systems. Although the pathogenesis of psoriasis remains far from elucidated, there are studies that delineate an involvement of oxidative stress in this skin disorder.

psoriasis oxidative stress reactive oxygen species antioxidants inflammation

1. Introduction

Psoriasis is a chronic, immune-mediated inflammatory dermatosis characterized by the appearance of erythematous plaques, covered by white scales, occasionally pruritogenic, and distributed mainly on the extensor areas (elbows, knees, scalp, chest) [1]. It is one of the most common chronic dermatological diseases, with a worldwide prevalence and incidence that varies significantly depending on geographical area, age and sex. For example, its prevalence varies from 0–2.1% in the pediatric population to 0.91–8.5% in adults, while its incidence is 40.8 cases in 100,000 people in the former and 78.9–230 cases in 100,000 in the latter [2]. Psoriasis is a debilitating condition, which significantly affects the quality of life and impacts on the life expectancy of individuals who suffer from it. Subjects diagnosed with this dermatological disorder experience feelings of depression, social stigma, and frequently associate other chronic systemic diseases, e.g., cardiovascular disease, obesity, diabetes, psoriasis no longer being considered a condition which strictly involves the integument [3][4]. The pathophysiology of the disease is still incompletely elucidated and multiple factors are said to be involved in its initiation and perpetuation, e.g., stressors, genetic factors, environmental factors (air pollutants, cigarette smoke), etc. [5]. In the last decade, a new theory is trying to explain the pathophysiology of this condition by looking at the role played by oxidative stress and chronic inflammation in the initiation of keratinocyte proliferation and differentiation that underline psoriasis [6]. Oxidative stress is defined as an imbalance or a transient or chronic increase in the levels of free oxygen/nitrogen radicals, either as a result of the exaggerated elevation in their production or the decrease in their ability to be eliminated by antioxidant systems [7]. Due to its role as a barrier and its direct exposure to environmental factors, the skin is an important source of free radicals that play, when in low concentrations, an essential role in the defense against microorganisms and in cell differentiation [8]. When their concentration increases, leading to oxidative stress, free radicals appear to be involved in DNA alteration, cell protein degradation, lipid oxidation, apoptosis, tissue injury, altered response of T-helper cells and secretion of interleukin-17 (IL-17) [9]. As all these are essential stages in the initiation and perpetuation of psoriasis, the hypothesis that oxidative stress plays a key role in the pathophysiology of this chronic dermatosis has emerged [10].

2. The Involvement of Oxidative Stress in Psoriasis

According to the data in the literature, oxidative stress plays an important role in initiating and perpetuating chronic diseases, e.g., cardiovascular, liver, neurological, metabolic, endocrinological and dermatological disorders [11]. Of the latter, psoriasis is an important representative, affecting a high percentage of the general population. The way in which these parameters reflect the level of oxidative stress in the body is difficult to assess, as so far there are no clear correlations between the oxidative balance and various oxidizing enzymes, antioxidant molecules or oxidation products, as the latter are generated in the body via multiple mechanisms including in physiological conditions [12][13]. The main source of reactive oxygen species remains the mitochondria, namely the mitochondrial inner membrane. Moreover, reactive oxygen species generation also results in the alteration of the main cellular components: lipids, carbohydrates and proteins [12][13]. Thus, at the lipid level, an increased number of reactive oxygen species is responsible for the enzymatic and non-enzymatic peroxidation of polyunsaturated fatty acids and LDL (with the formation of oxidized LDL), affecting the cell membrane and eventually leading to apoptosis [14]. Regarding the action of reactive oxygen species on the protein and carbohydrate components, their presence is associated with the formation of carbonyl-type compounds, advanced glycation end-products and advanced oxidation protein products, with an additional role of stimulating reactive oxygen species-generating processes at the cellular level. In addition to mitochondrial free radicals, a large number of reactive species also result from the action of pro-oxidant enzymes, such as xanthine oxidase, nitric oxide synthase, myeloperoxidase and NADPH oxidase. The body’s defense mechanisms against the increase in ROS levels above the physiological levels consist of enzymatic antioxidant systems (superoxide dismutase, catalase, glutathione peroxidase, etc.) which act as scavengers that capture the already formed free radicals, but also non-enzymatic antioxidant systems (glutathione, antioxidant vitamins) that have the role of interrupting reactive species-generating reactions [14]. Thus, glutathione, one of the main antioxidant systems, has the role of decreasing the reactive oxygen species concentrations via donation of a hydrogen ion with a neutralizing role. Thus, oxidized glutathione is generated [15]. Moreover, the increase in reactive oxygen species also causes changes at the nuclear level, by activating the transcription factors Nrf2 (nuclear factor erythroid related factor 2) and NF-kB (nuclear factor kappa light chain enhancer of activated B cells) which further contribute to the anti-oxidative stress defense mechanisms by inducing the synthesis of antioxidant molecules [14].

Figure 1 depicts role of oxidative stress in the initiation and evolution of psoriasis and its associated comorbidities.
Antioxidants 11 00282 g002 550
Figure 1. Oxidative stress in the psoriasis evolution. Oxidative stress plays an important role in the initiation and evolution of psoriasis and its associated-comorbidities/complications (cardiovascular diseases, psoriasis arthritis and autoimmune diseases. These complications are generated by the chronic action of ROS and RNS on the main cell constituents (lipids, proteins and carbohydrates), with a secondary activation of molecular pathways (Nrf2, NF-kB) responsible for inducing synthesis of antioxidant molecules (Nrf2) or pro-oxidant enzymes (NF-kB). ROS—reactive oxygen species; RNS—reactive nitrogen species; Nrf2—nuclear erythroid factor 2-related factor 2; NF-kB—nuclear factor kappa light chain enhancer of activated B cells; PUFAs—polyunsaturated fatty acids; AGE—advanced glycation end-products; PCO—protein carbonyl content.
Thus, following the analysis of the studies, most papers delineated a significant alteration of the redox balance, with a significant decrease in antioxidant enzymes and antioxidant markers and an increase in pro-oxidant molecules in psoriasis. A conundrum of research endeavors which collected venous blood samples from individuals suffering from psoriasis with variable duration of the disease detected low levels of total antioxidant status [16][17][18][19][20][21][22][23] and alterations in enzymes involved in decreasing free oxygen radicals concentrations, i.e., catalase [24][25][26][27][19][21][28], superoxide dismutase [26][19][21][28][22][29], paraoxonase-1 [30][31][26][32][33][20] and glutathione peroxidase [34][22]. Several studies with contradictory results were also present, highlighting that in psoriasis a significant elevation in the levels of the aforementioned antioxidant molecules can also occur [35][34][28][29]. We may hypothesize that, in psoriasis, there is a compensatory increase in antioxidant systems in order to counterbalance the elevated levels of oxidative stress. The plasma concentrations of pro-oxidant molecules was notably increased in all studies, reinforcing the theory that oxidative stress is a key player in the pathogenesis of this disease. The main indices assessed were total oxidative status, reactive oxygen species, myeloperoxidase, ischemia modified albumin, advanced glycation end-products and advanced oxidation protein products whose values were higher in subjects with psoriasis versus their healthy counterparts [35][36][37][38][24][25][39][40][41][16][42][18][43]. Moreover, some of these markers were correlated with the duration and severity of the disease, as well as indices of atherosclerosis. Consequently, these data support the contribution of oxidative stress to the development and evolution of the aforementioned illnesses, as well as to the crosstalk of psoriasis and several cardiometabolic comorbidities, i.e., atherosclerosis, hypertension or obesity, with which it is commonly associated [38][31][44][45][46]. In addition, several gene polymorphisms in genes encoding molecules with a role in the redox balance, such as glutathione S-transferase M1/glutathione S-transferase T1, paraoxonase-1, methylentetrahydrofolatereductase, glutathione S-transferase and catalase were upregulated or more frequently expressed in psoriasis [47][48][49][50][51][52][53][54]. For example, an enzyme with an important role in the psoriasis-associated comorbidities is paraoxonase-1. Paraoxonase-1 plays an antioxidant role, both by protecting LDL against peroxidation and by its direct role in eliminating oxidized forms of fatty acids, thus having both an antioxidant and an antiatherogenic action. Psoriasis is associated with the presence of paraoxonase-1gene polymorphisms that cause a low paraoxonase-1 activity, as well as an increase in oxidative stress [48]. Moreover, certain polymorphisms (paraoxonase-1 55 M > L) appear to be factors that directly impact on one’s risk of developing psoriasis [52].
On one hand, the use of anti-psoriasis therapy displayed promising results in reducing oxidative stress levels. On the other hand, the interpretation of the findings of studies exploring this research topic must be conducted with caution. Only a limited number of papers was published on this subject, involving a small number of cases but a wide range of management options, varying from systemic therapy, i.e., the immunosuppressive agent methotrexate and monoclonal antibodies, to local approaches, e.g., phototherapy. Thus, although biological agents and phototherapy seem to be linked with a decrease in reactive oxygen species and malondialdehyde and an increase in total antioxidant status, these results were not confirmed by all investigated papers. Of these, some highlighted a reduction in total antioxidant status and a paralleled elevation in total oxidative status despite disease amelioration [55][56][57][58][59]. Moreover, methotrexate has been proven to display pro-oxidant effects and it is known that this pharmacological agent enhances oxidative stress levels, mainly via post-administration generation of reactive oxygen species and malondialdehyde [60]. However, methotrexate has a dual effect on oxidative stress levels. On one hand, it enhances the generation of reactive oxygen species and, on the other hand, it inhibits the synthesis of nitric oxide. The administration of methotrexate is, thus, associated with a decrease in nitric oxide concentrations [60]. Thus, the antiproliferative and immunosuppressive effects of this pharmacological agent in psoriasis are mainly determined by the aforementioned increase in reactive oxygen species that induces the apoptosis of keratinocytes [60][55]. This pro-oxidant effect is also responsible for some of the side effects of this therapy which seem to be alleviated by the administration of antioxidant compounds [55]. Another molecule with antioxidant and protective roles is paraoxonase-1 which in patients with psoriasis treated with methotrexate is present in low concentrations, possibly due to the toxic effect of methotrexate on the liver which is the synthesis site of paraoxonase-1 [55].
Other pharmacological agents commonly used in the treatment of psoriasis are TNF-alpha inhibitors, namely infliximab. The use of this drug is associated with a decrease in oxidative stress levels due to its property to block the pro-oxidant role of TNF-alpha. Moreover, as opposed to the use of methotrexate which is linked with an elevation in pro-oxidant levels, infliximab does not influence the pro-oxidant/antioxidant balance or can influence it in the favor of antioxidant molecules [61].

3. Conclusions

Oxidative stress seems to be involvement in the development and evolution of psoriasis and its associated comorbidities, in particular those affecting cardiometabolic health. The utility of the assessment of circulating serum, plasma, urinary and/or skin biomarkers of oxidative stress and of the study of polymorphisms in genes regulating the redox balance remains to be explored in future prospective cohort studies. However, the role that oxidative stress plays in the pathophysiology of psoriasis is indisputable and understanding the mechanisms by which it contributes to the initiation and maintenance of this chronic condition can aid the management of this dermatosis in the near future. Thus, such markers may emerge as essential tools in the early diagnosis of psoriasis, from the subclinical stage, as well as in evaluating the pattern of evolution and the therapeutic response.

References

  1. Rendon, A.; Schäkel, K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019, 20, 1475.
  2. Parisi, R.; Symmons, D.P.M.; Griffiths, C.E.M.; Ashcroft, D.M.; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J. Investig. Dermatol. 2013, 133, 377–385.
  3. Sarkar, R.; Chugh, S.; Bansal, S. General measures and quality of life issues in psoriasis. Indian Dermatol. Online J. 2016, 7, 481–488.
  4. Oliveira, M.D.F.S.P.D.; Rocha, B.D.O.; Duarte, G.V. Psoriasis: Classical and emerging comorbidities. An. Bras. Dermatol. 2015, 90, 9–20.
  5. Kamiya, K.; Kishimoto, M.; Sugai, J.; Komine, M.; Ohtsuki, M. Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci. 2019, 20, 4347.
  6. Pleńkowska, J.; Gabig-Cimińska, M.; Mozolewski, P. Oxidative Stress as an Important Contributor to the Pathogenesis of Pso-riasis. Int. J. Mol. Sci. 2020, 21, 6206.
  7. Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative Stress: Harms and Benefits for Human Health. Oxid. Med. Cell. Longev. 2017, 2017, 8416763.
  8. Poljšak, B.; Dahmane, R. Free Radicals and Extrinsic Skin Aging. Dermatol. Res. Pract. 2012, 2012, 1–4.
  9. Dizdaroglu, M.; Jaruga, P.; Birincioglu, M.; Rodriguez, H. Free Radical-Induced Damage to DNA: Mechanisms and Measurement. Free Radic. Biol. Med. 2002, 32, 1102–1115.
  10. Bickers, D.R.; Athar, M. Oxidative Stress in the Pathogenesis of Skin Disease. J. Investig. Dermatol. 2006, 126, 2565–2575.
  11. Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; DELLA-Morte, D.; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D.; et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging 2018, 13, 757–772.
  12. Noeman, S.A.; Hamooda, H.E.; Baalash, A.A. Biochemical Study of Oxidative Stress Markers in the Liver, Kidney and Heart of High Fat Diet Induced Obesity in Rats. Diabetol. Metab. Syndr. 2011, 3, 17–18.
  13. Snezhkina, A.V.; Kudryavtseva, A.V.; Kardymon, O.L.; Savvateeva, M.V.; Melnikova, N.V.; Krasnov, G.S.; Dmitriev, A.A. ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells. Oxid. Med. Cell. Longev. 2019, 2019, 6175804.
  14. Marrocco, I.; Altieri, F.; Peluso, I. Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. Oxid. Med. Cell. Longev. 2017, 2017, 1–32.
  15. Armstrong, J.S.; Steinauer, K.K.; Hornung, B.; Irish, J.; Lecane, P.; Birrell, G.; Peehl, D.M.; Knox, S.J. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ. 2002, 9, 252–263.
  16. Sürücü, H.A.; Aksoy, N.; Ozgöztas, O.; Sezen, H.; Yesilova, Y.; Turan, E. Prolidase Activity in Chronic Plaque Psoriasis Pa-tients. Postepy Dermatol. Alergol. 2015, 32, 82–87.
  17. Chandrashekar, L.; Kumari, G.R.K.; Rajappa, M.; Revathy, G.; Munisamy, M.; Thappa, D. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br. J. Biomed. Sci. 2015, 72, 56–60.
  18. Emre, S.; Metin, A.; Demirseren, D.D.; Kilic, S.; Isikoglu, S.; Erel, O. The Relationship between Oxidative Stress, Smoking and the Clinical Severity of Psoriasis: Oxidative Stress and Smoking in Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2013, 27, e370–e375.
  19. Gabr, S.A.; Al-Ghadir, A.H. Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. Arch. Dermatol. Res. 2012, 304, 451–457.
  20. Ferretti, G.; Bacchetti, T.; Campanati, A.; Simonetti, O.; Liberati, G.; Offidani, A. Correlation between Lipoprotein(a) and Lipid Peroxidation in Psoriasis: Role of the Enzyme Paraoxonase-1: Lp(a) and Paraoxonase-1 in Psoriasis. Br. J. Dermatol. 2012, 166, 204–207.
  21. Kadam, D.P.; Suryakar, A.N.; Ankush, R.D.; Kadam, C.Y.; Deshpande, K.H. Role of Oxidative Stress in Various Stages of Psoriasis. Indian J. Clin. Biochem. 2010, 25, 388–392.
  22. Kural, B.V.; Örem, A.; Çimşit, G.; Yandı, Y.E.; Calapoǧlu, M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant–antioxidant system in patients with psoriasis. Clin. Chim. Acta 2003, 328, 71–82.
  23. Baz, K.; Cimen, M.Y.B.; Kokturk, A.; Yazici, A.C.; Eskandari, G.; Ikizoglu, G.; Api, H.; Atik, U. Oxidant/Antioxidant Status in Patients with Psoriasis. Yonsei Med. J. 2003, 44, 987–990.
  24. Wójcik, P.; Gęgotek, A.; Wroński, A.; Jastrząb, A.; Żebrowska, A.; Skrzydlewska, E. Effect of redox imbalance on protein modifications in lymphocytes of psoriatic patients. J. Biochem. 2019, 167, 323–331.
  25. Esmaeili, B.; Mansouri, P.; Doustimotlagh, A.H.; Izad, M. Redox imbalance and IL-17 responses in memory CD4+ T cells from patients with psoriasis. Scand. J. Immunol. 2018, 89, e12730.
  26. Nemati, H.; Khodarahmi, R.; Sadeghi, M.; Ebrahimi, A.; Rezaei, M.; Vaisi-Raygani, A. Antioxidant Status in Patients with Psoriasis: Antioxidant in Patients with Psoriasis. Cell Biochem. Funct. 2014, 32, 268–273.
  27. Pujari, V.M.; Ireddy, S.; Itagi, I.; Kumar, H.S. The Serum Levels of Malondialdehyde, Vitamin e and Erythrocyte Catalase Activity in Psoriasis Patients. J. Clin. Diagn. Res. 2014, 8, CC14-6.
  28. Karaman, A.; Aliagaoglu, C.; Pirim, I. Sister chromatid exchange analysis in patients with psoriasis. Exp. Dermatol. 2008, 17, 524–529.
  29. Yildirim, M.; Inaloz, H.S.; Baysal, V.; Delibas, N. The role of oxidants and antioxidants in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2003, 17, 34–36.
  30. Oszukowska, M.; Kozłowska, M.; Kaszuba, A. Paraoxonase-1 and other factors related to oxidative stress in psoriasis. Adv. Dermatol. Allergol. 2020, 37, 92–96.
  31. Husni, M.E.; Tang, W.H.W.; Lucke, M.; Chandrasekharan, U.M.; Ms, D.M.B.; Hazen, S.L. Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity with Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. Arthritis Rheumatol. 2018, 70, 1240–1250.
  32. He, L.; Qin, S.; Dang, L.; Song, G.; Yao, S.; Yang, N.; Li, Y. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2014, 1841, 1709–1715.
  33. Usta, M.; Turan, E.; Aral, H.; Inal, B.B.; Gurel, M.S.; Guvenen, G. Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome. J. Clin. Lab. Anal. 2011, 25, 289–295.
  34. Ambrożewicz, E.; Wójcik, P.; Wroński, A.; Łuczaj, W.; Jastrząb, A.; Žarković, N.; Skrzydlewska, E. Pathophysiological Alter-ations of Redox Signaling and Endocannabinoid System in Granulocytes and Plasma of Psoriatic Patients. Cells 2018, 7, 159.
  35. Kirmit, A.; Kader, S.; Aksoy, M.; Bal, C.; Nural, C.; Aslan, O. Trace elements and oxidative stress status in patients with psoriasis. Adv. Dermatol. Allergol. 2020, 37, 333–339.
  36. Skutnik-Radziszewska, A.; Maciejczyk, M.; Fejfer, K.; Krahel, J.; Flisiak, I.; Kołodziej, U.; Zalewska, A. Salivary Antioxidants and Oxidative Stress in Psoriatic Patients: Can Salivary Total Oxidant Status and Oxidative Status Index Be a Plaque Psoriasis Biomarker? Oxid. Med. Cell. Longev. 2020, 2020, 9086024.
  37. Kızılyel, O.; Akdeniz, N.; Metin, M.S.; Elmas, Ö.F. Investigation of Oxidant and Antioxidant Levels in Patients with Psoriasis. Turk. J. Med. Sci. 2019, 49, 1085–1088.
  38. Ergun, T.; Yazici, V.; Yavuz, D.; Seckin-Gencosmanoglu, D.; Ozen, G.; Salman, A.; Direskeneli, H.; Inanc, N. Advanced Gly-cation End Products, a Potential Link between Psoriasis and Cardiovascular Disease: A Case-Control Study. Indian J. Dermatol. 2019, 64, 201–206.
  39. Haberka, M.; Bańska-Kisiel, K.; Bergler-Czop, B.; Biedroń, M.; Brzezińska-Wcisło, L.; Okopień, B.; Gąsior, Z. Mild to Moderate Psoriasis Is Associated with Oxidative Stress, Subclinical Atherosclerosis, and Endothelial Dysfunction. Pol. Arch. Intern. Med. 2018, 128, 434–439.
  40. Papagrigoraki, A.; Giglio, M.; Cosma, C.; Maurelli, M.; Girolomoni, G.; Lapolla, A. Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis. Acta Derm. Venereol. 2017, 97, 782–787.
  41. Dilek, N.; Dilek, A.R.; Taşkın, Y.; Erkinüresin, T.; Yalçın, Ö.; Saral, Y. Contribution of myeloperoxidase and inducible nitric oxide synthase to pathogenesis of psoriasis. Adv. Dermatol. Allergol. 2016, 33, 435–439.
  42. Damasiewicz-Bodzek, A.; Wielkoszyński, T. Advanced Protein Glycation in Psoriasis: Protein Glycation in Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2012, 26, 172–179.
  43. Ozdemir, M.; Kiyici, A.; Balevi, A.; Mevlitoğlu, I.; Peru, C. Assessment of Ischaemia-Modified Albumin Level in Patients with Psoriasis: Psoriasis and Ischaemia-Modified Albumin. Clin. Exp. Dermatol. 2012, 37, 610–614.
  44. Singal, A.; Asha, K.; Sharma, S.B.; Arora, V.K.; Aggarwal, A. Dyslipidaemia & oxidative stress in patients of psoriasis: Emerging cardiovascular risk factors. Indian J. Med. Res. 2017, 146, 708–713.
  45. Sunitha, S.; Rajappa, M.; Thappa, D.M.; Chandrashekar, L.; Munisamy, M.; Revathy, G. Is the Ratio of Antibodies Against Oxidized LDL to Oxidized LDL an Indicator of Cardiovascular Risk in Psoriasis? Oman Med. J. 2016, 31, 390–393.
  46. Ikonomidis, I.; Makavos, G.; Papadavid, E.; Varoudi, M.; Andreadou, I.; Gravanis, K.; Theodoropoulos, K.; Pavlidis, G.; Tri-antafyllidi, H.; Parissis, J.; et al. Similarities in Coronary Function and Myocardial De-formation between Psoriasis and Coronary Artery Disease: The Role of Oxidative Stress and Inflammation. Can. J. Cardiol. 2015, 31, 287–295.
  47. Hernández-Collazo, A.A.; Pérez-Méndez, O.; López-Olmos, V.; Delgado-Rizo, V.; Muñoz-Valle, J.F.; Martínez-López, E.; Villanueva-Quintero, D.G.; Domínguez-Díaz, C.; Fafutis-Morris, M.; Alvarado-Navarro, A. Association between rs662 (A > G) and rs854560 (A > T) polymorphisms in PON1 gene and the susceptibility for psoriasis in mestizo population of Western Mexico. Mol. Biol. Rep. 2021, 48, 183–194.
  48. Guarneri, F.; Sapienza, D.; Papaianni, V.; Marafioti, I.; Guarneri, C.; Mondello, C.; Roccuzzo, S.; Asmundo, A.; Cannavò, S.P. Association between Genetic Polymorphisms of Glutathione S-Transferase M1/T1 and Psoriasis in a Population from the Area of the Strict of Messina (Southern Italy). Free Radic. Res. 2020, 54, 57–63.
  49. Solak, B.; Karkucak, M.; Turan, H.; Ocakoğlu, G.; Şebnem Özemri, S.; Uslu, E.; Yakut, T.; Erdem, T. Glutathione S-Transferase M1 and T1 Gene Polymorphisms in Patients with Chronic Plaque-Type Psoriasis: A Case-Control Study. Med. Princ. Pract. 2015, 25, 155–158.
  50. Chang, Y.-C.; Wu, W.-M.; Huang, Y.-H.; Hung, S.-I.; Tsai, H.-Y.; Hsu, L.-A. The (CCTTT) n pentanucleotide repeat polymorphism in the inducible nitric oxide synthase gene promoter and the risk of psoriasis in Taiwanese. Arch. Dermatol. Res. 2015, 307, 425–432.
  51. Asefi, M.; Vaisi-Raygani, A.; Khodarahmi, R.; Nemati, H.; Rahimi, Z.; Tavilani, H.; Pourmotabbed, T. Methylentetrahydrofolatereductase (rs1801133) polymorphism and psoriasis: Contribution to oxidative stress, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 1192–1198.
  52. Asefi, M.; Vaisi-Raygani, A.; Bahrehmand, F.; Kiani, A.; Rahimi, Z.; Nomani, H.; Ebrahimi, A.; Tavilani, H.; Pourmotabbed, T. Paraoxonase 1 (PON1) 55 Polymorphism, Lipid Profiles and Psoriasis: Paraoxonase 55 Polymorphism and Psoriasis. Br. J. Dermatol. 2012, 167, 1279–1286.
  53. Schnorr, O.; Schuier, M.; Kagemann, G.; Wolf, R.; Walz, M.; Ruzicka, T.; Mayatepek, E.; Laryea, M.; Suschek, C.V.; Kolb-Bachofen, V.; et al. Arginase-1 overexpression induces cationic amino acid transporter-1 in psoriasis. Free Radic. Biol. Med. 2005, 38, 1073–1079.
  54. Vasku, V.; Kankova, K.; Vasku, A.; Muzik, J.; Hollá, L.I.; Semrádová, V.; Vácha, J. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch. Dermatol. Res. 2002, 294, 127–130.
  55. Kılıc, S.; Emre, S.; Metin, A.; Isıkoglu, S.; Erel, O. Effect of the systemic use of methotrexate on the oxidative stress and paraoxonase enzyme in psoriasis patients. Arch. Dermatol. Res. 2013, 305, 495–500.
  56. Wacewicz, M.; Socha, K.; Soroczyńska, J.; Niczyporuk, M.; Aleksiejczuk, P.; Ostrowska, J.; Borawska, M.H. Concentration of Selenium, Zinc, Copper, Cu/Zn Ratio, Total Antioxidant Status and c-Reactive Protein in the Serum of Patients with Psoriasis Treated by Narrow-Band Ultraviolet B Phototherapy: A Case-Control Study. J. Trace Elem. Med. Biol. 2017, 44, 109–114.
  57. Karadag, A.S.; Uzunçakmak, T.K.; Ozkanli, S.; Oguztuzun, S.; Moran, B.; Akbulak, O.; Ozlu, E.; Zemheri, I.E.; Bilgili, S.G.; Akdeniz, N. An investigation of cytochrome p450 (CYP) and glutathioneS-transferase (GST) isoenzyme protein expression and related interactions with phototherapy in patients with psoriasis vulgaris. Int. J. Dermatol. 2016, 56, 225–231.
  58. Pektas, S.; Akoglu, G.; Metin, A.; Neselioglu, S.; Erel, O. Evaluation of systemic oxidant/antioxidant status and paraoxonase 1 enzyme activities in psoriatic patients treated by narrow band ultraviolet B phototherapy. Redox Rep. 2013, 18, 200–204.
  59. Pastore, S.; Mariani, V.; Lulli, D.; Gubinelli, E.; Raskovic, D.; Mariani, S.; Stancato, A.; De Luca, C.; Pecorelli, A.; Valacchi, G.; et al. Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab. Free Radic. Res. 2011, 45, 585–599.
  60. Elango, T.; Dayalan, H.; Gnanaraj, P.; Malligarjunan, H.; Subramanian, S. Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin. Exp. Med. 2014, 14, 431–437.
  61. Barygina, V.; Becatti, M.; Soldi, G.; Prignano, F.; Lotti, T.; Nassi, P.; Wright, D.; Taddei, N.; Fiorillo, C. Altered redox status in the blood of psoriatic patients: Involvement of NADPH oxidase and role of anti-TNF-α therapy. Redox Rep. 2013, 18, 100–106.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Dermatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mihnea-Alexandru Gaman
,
Amelia Maria Gaman
View Times: 740
Revisions: 2 times (View History)
Update Date: 10 Feb 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback